<DOC>
	<DOCNO>NCT01943838</DOCNO>
	<brief_summary>Primary Objective : - To assess safety , tolerability plasma pharmacokinetics ( PK ) SAR245408 give daily tablet formulation polymorph E subject solid tumor lymphoma .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics SAR245408 Tablets Patients With Solid Tumors Lymphoma</brief_title>
	<detailed_description>Screening : 1 28 day Study treatment period : two 28-day cycle ( 56 day ) End-of-treatment visit : later 7 day last study drug administration Subjects eligible treatment continuation Cycle 2 follow safety ; follow-up visit perform within 30 Â± 3 day last study drug administration Subjects eligible treatment continuation Cycle 2 offer opportunity enroll treatment-extension study TED12414 . Total duration study participation patient : 58 118 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Solid tumor metastatic unresectable , relapsed refractory lymphoma ( include chronic lymphocytic leukemia/small lymphocytic lymphoma ) , standard therapy longer effective therapy know prolong survival patient tolerate contraindication standard therapy alternative therapy . Male female patient &gt; = 18 year old . Weight &gt; = 40 kg . Eastern Cooperative Oncology Group performance status &lt; = 1 . Adequate white blood cell , platelet , haemoglobin . Adequate liver kidney function . Fasting plasma glucose &lt; 8.9 mmol/L . Sexually active patient use adequate contraception . Women childbearing potential negative pregnancy test . Exclusion criterion : Lymphoma involve gastrointestinal tract . Prior treatment cytotoxic chemotherapy ( include investigational agent ) biologic agent ( antibody , immune modulators , cytokine ) within 4 week , nitrosoureas mitomycin C within 6 week , first dose study drug . Prior treatment smallmolecule kinase inhibitor ( include investigational agent ) within 2 week , 5 half life drug active metabolite , whichever longer , first dose study drug . Any investigational therapy within 4 week first dose study drug . Intolerance prior treatment PI3K inhibitor . Prior anticancer hormonal therapy within 2 week first dose study drug . Prior radiation therapy within 2 week first dose study drug . Uncontrolled brain metastasis primary brain tumor . Hereditary acquire immunodeficiency syndrome human immunodeficiency virus ( HIV ) infection . Positive serology Hepatitis B surface antigen ( HBsAg ) antiHepatitis C virus ( antiHCV ) antibody . Patient pregnant breastfeeding . History gastrointestinal surgery , presence gastrointestinal abnormality disease , may affect pharmacokinetics study drug . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>